Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913468 · ClinicalTrials.gov registry record
Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 206
- Enrollment target
NCT03913468: Completed study, sponsored by University of Wisconsin, Madison.
NCT03913468 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 206 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03913468 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 206 participants
- Enrollment target
Study Summary
This is a retrospective chart review that will measure the impact on outcomes in septic shock patients who were resuscitated with a novel combination of medicines called iHAT (intravenous hydrocortisone -ascorbic acid-thiamine). Septic shock patients treated with this combination of drugs over the past two years will be compared with similar, concurrent septic shock patients who were not treated with this drug given that adoption of this therapy has been variable.
Primary Outcome
Length of time requiring IV vasopressors
Interventions
- DRUG Intravenous Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2019-12-01 |
What the finished NCT03913468 record still lists
NCT03913468 is an observational study that tracks outcomes without assigning an intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Intravenous Ascorbic Acid is the first listed.
NCT03913468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03913468 about?
NCT03913468 is a clinical study titled "Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.". This is a retrospective chart review that will measure the impact on outcomes in septic shock patients who were resuscitated with a novel combination of medicines called iHAT (intravenous hydrocortisone -ascorbic acid-thiamine). Septic shock patients treated with this combination of drugs over the p...
What is the current status of trial NCT03913468?
This trial is currently completed. The enrollment target is 206 participants. The study started on 2019-01-01. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT03913468?
The interventions under investigation include: Intravenous Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT03913468?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI